Quidel Stock Price, News & Analysis

Quidel Corporation (NASDAQ: QDEL) reported **record financial results** for Q1 2022, with **total revenues of $1,002.3 million**, a **167% increase** year-over-year from $375.3 million. **COVID-19 product sales** surged **211%** to $836.1 million. The company's **GAAP EPS** reached **$11.31**, compared to **$4.09** in Q1 2021. **Gross profit** was $740.0 million, equating to **74% of revenue**, down from **80%** the previous year. The company anticipates growth from its **planned acquisition of Ortho Clinical Diagnostics**, aiming to enhance market penetration and diagnostics capabilities.

Quidel Corporation (NASDAQ: QDEL) will report its fiscal Q1 2022 financial results after market close on May 4, 2022. Following this, a conference call will take place with CEO Douglas Bryant and CFO Randy Steward at 5:00 p.m. ET to discuss the results and business trends. Investors can join the call via telephone or a live webcast. The company is recognized for its rapid diagnostic testing solutions, including COVID-19 tests. Its innovative products have enhanced healthcare quality globally, establishing Quidel as a key player in the medical device industry.

Quidel Corporation (NASDAQ: QDEL) anticipates first-quarter 2022 revenues between $990 million and $1,000 million, a substantial increase of 164% to 166% compared to $375.3 million in Q1 2021. The expected COVID-19 product revenues are approximately $836 million, with about $657 million from QuickVue® and $138 million from Sofia® tests. With over 113 million QuickVue tests sold, Quidel is poised for strong annual performance while expanding its diagnostic testing capabilities.

Quidel Corporation (NASDAQ: QDEL) announced its participation in the Raymond James 43rd Annual Institutional Investors Conference on March 9, 2022, at 10:25 a.m. ET in Orlando, Florida. CEO Douglas Bryant and CFO Randy Steward will present insights on the company's business and financial developments, followed by a Q&A session. A live webcast will be available through Quidel's Investor Relations website, with a replay accessible for 14 days post-event. Quidel is recognized for its diagnostic solutions and rapid testing technologies, enhancing global healthcare.

Quidel Corporation (NASDAQ: QDEL) reported fourth quarter 2021 revenue of $636.9 million, a decline from $809.2 million in 2020, primarily due to a $249 million drop in Sofia product sales. Although COVID-19 product revenue increased 42% to $1.27 billion for the year, GAAP EPS decreased to $6.85, down from $10.78 in Q4 2020. The company is expanding into retail testing markets and has a definitive agreement to acquire Ortho Clinical Diagnostics. Full year gross profit was $1.27 billion, down from $1.34 billion in 2020.

Quidel Corporation (NASDAQ: QDEL) will release its fiscal fourth quarter and full-year 2021 financial results on February 17, 2022, after market close. Following this, CEO Douglas Bryant and CFO Randy Steward will host a conference call at 5:00 p.m. ET to discuss the results and answer investor questions. The call will cover business developments and financial trends, with material information likely included. Investors can join by phone or via a webcast, with replays accessible for one year for the webcast and 14 days for the phone replay.

Quidel Corporation (NASDAQ: QDEL) announced projected revenues for Q4 2021 between $633 million and $637 million, with COVID-19 revenues expected around $510 million. The company highlights significant achievements in 2021, including the opening of a major immunoassay manufacturing facility and the acquisition agreement for Ortho Clinical Diagnostics. Quidel sold nearly 77 million rapid tests in Q4 and plans to enhance its product offerings in 2022 with the introduction of new technologies.

Quidel Corporation (NASDAQ: QDEL) announces the availability of a public health webinar on Bartonella species, the cause of Bartonellosis. Conducted by Dr. Monica E. Embers, the webinar discusses clinical presentations of Bartonellosis, its comparison with Lyme disease, and highlights research needs for better diagnosis and treatment. The event is relevant as Lyme disease cases surged to nearly 476,000 in 2021. Quidel, a leader in diagnostic solutions, aims to enhance healthcare through rapid testing technologies.

Quidel Corporation (NASDAQ: QDEL) will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 1:30 p.m. Eastern time. Douglas Bryant, the CEO, will discuss the company's business and financial developments, followed by a Q&A session. A live webcast of the presentation will be available on Quidel's Investor Relations website, along with an audio archive for 14 days post-event. Quidel is a leader in rapid diagnostic testing solutions and aims to enhance global healthcare quality.